OPKO Health (OPK) And Entera Bio Announce Data for GLP-2 [Yahoo! Finance]
Opko Health, Inc. (OPK)
Last opko health, inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NYSE Investor Relations:
investor.opko.com
Company Research
Source: Yahoo! Finance
exclusive N-Tab technology with a long-acting, proprietary GLP-2 agonist created by OPK. The program's primary objective is to create the first and only GLP-2 peptide pill substitute for individuals with short bowel syndrome (SBS) and other conditions that cause inflammation of the mucosa and loss of nutrients. More on Short Bowel Syndrome SBS is a rare and potentially life-threatening malabsorptive condition caused by a significant loss of functional bowel mass or physical bowel mass. SBS patients have a reduced ability to absorb nutrients and fluids and are at risk of malnutrition, unintended weight loss and additional symptoms due to the loss of essential vitamins and minerals. More on the Study The program's primary goal is to create the first and only GLP-2 peptide pill substitute for individuals with short bowel syndrome and other conditions characterized by inflammation of the mucosa and loss of nutrients. The only GLP-2 agonist that is currently licensed for use is T
Show less
Read more
Impact Snapshot
Event Time:
OPK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OPK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OPK alerts
High impacting Opko Health, Inc. news events
Weekly update
A roundup of the hottest topics
OPK
News
- GeneDx Announces Partnership with Komodo Health to Expand Access to World's Largest Rare Disease Dataset [Yahoo! Finance]Yahoo! Finance
- GeneDx to Report First Quarter 2024 Financial Results on Monday, April 29, 2024 [Yahoo! Finance]Yahoo! Finance
- OPKO Health, Inc. (NASDAQ: OPK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.MarketBeat
- OPKO Health (OPK) to Restructure After Asset Buyout by Labcorp [Yahoo! Finance]Yahoo! Finance
- OPKO Health, Inc. (NASDAQ: OPK) had its "outperform" rating re-affirmed by analysts at Barrington Research. They now have a $1.50 price target on the stock.MarketBeat
OPK
Earnings
- 2/27/24 - In-Line
OPK
Sec Filings
- 3/29/24 - Form 4
- 3/29/24 - Form 4
- 3/29/24 - Form 4
- OPK's page on the SEC website